1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23301
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorGennatas, K.en
dc.contributor.authorBeer, M.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorKarpathios, S.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorKonstantaras, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:31:39Z-
dc.date.available2015-11-24T19:31:39Z-
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23301-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/*therapeutic useen
dc.subjectCarcinoma/*drug therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapyen
dc.subjectPrognosisen
dc.subjectProspective Studiesen
dc.subjectRemission Inductionen
dc.subjectSurvival Analysisen
dc.subjectSurvival Rateen
dc.titleCarboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8814685-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractWe compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB-EC) in advanced ovarian cancer patients. The treatment was scheduled to be administered every 3 weeks for six courses. Following initial laparotomy and cytoreductive surgery, 130 previously untreated patients entered the study. 73 patients were treated with carboplatin alone while 57 received the combination chemotherapy. In the majority of the patients, the regimens had to be given every 4 weeks due to myelosuppression. Nausea, vomiting and alopecia were more severe in the CB-EC arm. Overall, clinical complete response was observed in 73 (56%) and partial response in 20 (15%) patients. The median time to progression was 16.89 months and median survival was 29.54 months. No significant differences in response rate, time to progression, disease-free survival and overall survival were observed between the two treatment arms. The prognostic role of residual disease after initial surgery, complete remission at second-look laparotomy, tumour stage and performance status was confirmed.en
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons